《中国慢性肾脏病矿物质和骨异常诊治指南》的解读与思考  

Interpretation and thinking of the“China guidelines for diagnosis and treatment of chronic kidney disease-mineral and bone disorder”

作　　者：余永武 周加军[2] 张凌[3] Yu Yongwu;Zhou JiaJun;Zhang Ling(Department of Nephrology,Chuiyangliu Hospital Affiliated to Tsinghua University,Beijing 100022;Blood Purification Center,Yijishan Hospital Affiliated to Wannan Medical College,Wuhu 241000,Anhui Province;Department of Nephrology,China-Japan Friendship Hospital,Beijing 100029,China)

机构地区：[1]清华大学附属垂杨柳医院,北京100022 [2]皖南医学院弋矶山医院,芜湖241000 [3]中日友好医院肾内科,北京100029

出　　处：《中华肾病研究电子杂志》2020年第1期17-21,共5页Chinese Journal of Kidney Disease Investigation（Electronic Edition）

基　　金：吴阶平医学基金支持项目(320.6750.18110)。

摘　　要：慢性肾脏病-矿物质和骨代谢异常(CKD-MBD)是慢性肾脏疾病最常见的并发症,是由于肾小球滤过率下降,导致多种物质、毒素潴留。临床上表现为血钙、磷及相关调节激素如甲状旁腺激素、维生素D和成纤维细胞生长因子23的紊乱,进而引起代谢性骨病或骨折、心血管疾病的发生,增加患者的住院率及病死率。2018年推出的《中国慢性肾脏病矿物质和骨异常诊治指南》为规范CKD-MBD诊疗起到了很好的作用。本文就CKD-MBD指南结合自己的临床经验体会予以解读。Chronic kidney disease-mineral and bone disorder(CKD-MBD)is the most common complication of chronic kidney disease.It is due to the decline in glomerular filtration rate,which leads to the retention of multiple substances and toxins.Its clinical manifestations includes disorders of blood calcium,phosphorus and related regulatory hormones such as parathyroid hormone,vitamin D,and fibroblast growth factor 23,which in turn cause metabolic bone disease or fractures,and cardiovascular diseases,and increase the hospitalization rate and mortality of patients.The“China guidelines for the diagnosis and treatment of CKD-MBD”launched in 2018 has played a very good role in standardizing the diagnosis and treatment of CKD-MBD.This article interpreted the CKD-MBD guidelines combing with the clinical experience of the authors.

关 键 词：慢性肾脏病-矿物质和骨代谢异常 继发性甲状旁腺功能亢进 

分 类 号：R69[医药卫生—泌尿科学]